Dapagliflozin: Nursing Drug Guide, Euglycemic DKA Risk & NCLEX Review
Healthcare medication guide: recognize euglycemic diabetic ketoacidosis with normal or near-normal glucose, enforce perioperative hold before NPO and surgery, and prevent volume depletion from osmotic diuresis—especially with loop diuretics or reduced oral intake.
Dapagliflozin and other SGLT2 inhibitors can cause euglycemic diabetic ketoacidosis (euDKA)—ketoacidosis with glucose that may be normal or only mildly elevated. The highest-stakes nursing failures are continuing the drug during NPO, illness, or perioperative fasting, not checking ketones when acidosis is suspected, and missing volume depletion from osmotic diuresis (especially with loop diuretics or poor intake). FDA labeling recommends withholding dapagliflozin for at least 3 days before major surgery or prolonged fasting; resume only when clinically stable with oral intake restored. Hold immediately when euDKA, significant hypotension, or necrotizing fasciitis of the perineum is suspected.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before any NPO period, surgery, or acute illness, confirm dapagliflozin is held per labeling (≥3 days before major surgery). If the patient has nausea, abdominal pain, tachypnea, or confusion—check ketones and BMP even when glucose looks acceptable; euDKA can hide behind near-normal sugars.
Most common brand names
Dapagliflozin is available as generic tablets and as the brand Farxiga (U.S.). International brand names include Forxiga and Edistride. Verify the MAR matches the ordered product—SGLT2 inhibitors are not interchangeable with DPP-4 inhibitors or GLP-1 agonists without a new prescriber order.
Why we give it — Indications
Dapagliflozin is an SGLT2 inhibitor used for glycemic control in type 2 diabetes, to reduce risk of hospitalization in heart failure, and to slow progression of chronic kidney disease (CKD) in adults with and without diabetes—each indication has different renal thresholds per FDA labeling.
| Use | Detail |
|---|---|
| Type 2 diabetes — glycemic control | Adjunct to diet and exercise; often combined with metformin or other agents. Not recommended for glycemic control when eGFR is below 45 mL/min/1.73 m² (reduced efficacy). |
| Heart failure | 10 mg once daily to reduce risk of cardiovascular death and heart-failure hospitalization in adults with heart failure (with or without type 2 diabetes). |
| Chronic kidney disease | 10 mg once daily to reduce risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and heart-failure hospitalization in adults with CKD at risk of progression. |
| Pediatrics (T2DM) | Approved for glycemic control in children ≥10 years with type 2 diabetes—same starting dose 5 mg once daily, may increase to 10 mg. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing reabsorption of filtered glucose and increasing urinary glucose excretion. This lowers plasma glucose independent of insulin secretion and produces osmotic diuresis with caloric loss. Nursing relevance: glucose on the meter may look acceptable while ketones rise during fasting, stress, or surgery—because the drug shifts metabolism and masks hyperglycemia, euDKA is the primary safety story nurses must not miss.
Dosing overview
Always verify indication, renal function (eGFR), and perioperative hold status before administration.
Renal dosing summary (FDA labeling)
| Indication | eGFR threshold | Nursing action |
|---|---|---|
| Type 2 diabetes (glycemic) | Not recommended if eGFR <45 mL/min/1.73 m² | Do not start or continue solely for glucose lowering below threshold; clarify indication with prescriber |
| CKD outcomes | 10 mg daily if eGFR ≥25; do not initiate if <25 | May continue 10 mg if eGFR falls below 25 while already on therapy for CKD per labeling |
| Heart failure | 10 mg once daily | Monitor volume status and renal function; hold perioperatively per labeling |
| Hepatic impairment | No dose adjustment mild–moderate–severe | Use caution in severe hepatic impairment—benefit-risk per prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: Take as soon as remembered unless near the next dose; do not double. After prolonged interruption (illness, NPO, surgery), confirm restart criteria with prescriber—do not resume automatically without stability and oral intake assessment.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Time to peak (oral) | Approximately 2 hours (labeling) | Once-daily dosing; timing with meals is flexible |
| Half-life | Approximately 12.9 hours | Perioperative hold ≥3 days allows washout before prolonged fasting |
| Elimination | Primarily renal (glucuronidation + renal excretion) | Renal function guides indication-specific use; trend creatinine with diuretics |
| Food effect | May take with or without food | Consistent daily timing supports adherence; hold overrides routine schedule perioperatively |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm indication (T2DM glycemic vs HF vs CKD)—renal thresholds differ
- Review latest eGFR/creatinine, volume status, blood pressure, and concurrent diuretics
- Verify perioperative hold: major surgery within 3 days, NPO, or prolonged fasting
- Assess for genital mycotic infection symptoms, pregnancy status, and allergy history
Contraindications
- History of serious hypersensitivity reaction to dapagliflozin
Important interactions and factors
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Loop/thiazide diuretics | Additive volume depletion and hypotension risk | Monitor orthostatics, I&O, creatinine; hold if symptomatic hypotension or AKI |
| Insulin / insulin secretagogues | Increased hypoglycemia risk when combined for glycemic control | Monitor for hypoglycemia symptoms; do not confuse with euDKA (check ketones) |
| NPO, surgery, acute illness | Elevated euDKA risk | Hold per labeling; ketone assessment when acidosis suspected regardless of glucose |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral: Swallow tablet whole once daily, with or without food, at approximately the same time each day. Do not crush or split unless pharmacy confirms an acceptable formulation.
- Confirm hold status on MAR before giving any dose during NPO or perioperative windows
- Document indication and renal eligibility (especially eGFR thresholds for T2DM vs CKD)
- Pair administration review with blood glucose monitoring and volume assessment—not glucose alone
Expected therapeutic response
- Improved glycemic control in type 2 diabetes—trend HbA1c and fasting glucose over weeks
- Reduced heart-failure hospitalization risk and symptom stability when used for HF indication
- Slower eGFR decline in eligible CKD patients on 10 mg daily
- Mild osmotic diuresis and weight reduction from caloric loss—monitor for excessive volume loss
Red flags — Stop and act
Euglycemic DKA and volume collapse can escalate quickly. Hold dapagliflozin and escalate immediately.
- Signs of diabetic ketoacidosis or euDKA: nausea, vomiting, abdominal pain, Kussmaul respirations, ketonuria—even if glucose is <250 mg/dL
- Confusion, lethargy, or altered mental status with metabolic acidosis cues
- Symptomatic hypotension, syncope, or dehydration with poor urine output
- Genital pain, erythema, swelling, or malodorous discharge suggesting necrotizing fasciitis (Fournier gangrene)—rare but life-threatening
- Serious hypersensitivity (angioedema, anaphylaxis)
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Genital mycotic infections | Common in trials; women > men | Teach hygiene; evaluate symptoms; treat per protocol; consider hold if recurrent/severe |
| Volume depletion / hypotension | Diuresis-related; higher with diuretics | Monitor orthostatics, I&O; encourage fluids when safe; hold if symptomatic |
| Nausea, thirst, polyuria | Osmotic diuresis | Differentiate from euDKA—check ketones and BMP if systemic symptoms |
| EuDKA | Serious; post-marketing and labeling warning | Hold drug, initiate DKA/euDKA protocol, notify prescriber urgently |
| Acute kidney injury | Associated with volume depletion | Hold, hydrate per order, trend creatinine on BMP |
| Hypoglycemia | When combined with insulin/secretagogues | Treat hypoglycemia per protocol; euDKA may coexist—do not rely on glucose alone |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
No reports of overdose occurred in clinical development per FDA labeling. In the event of suspected overdose, remove the source and provide supportive care based on clinical status.
Management
- Supportive treatment of volume status, glucose, ketones, and electrolytes per clinical presentation
- Hemodialysis removal of dapagliflozin has not been studied
- No specific antidote is listed in prescribing information
- Contact local poison control or toxicology services per facility protocol if overdose is suspected
Look-alike / sound-alike and error prevention
- Dapagliflozin vs other SGLT2 inhibitors—different agents (e.g., empagliflozin); verify generic name on MAR
- Farxiga vs Forxiga—same molecule, regional brand spelling; confirm correct product
- 5 mg vs 10 mg—independent double-check; CKD/HF uses 10 mg; T2DM may start at 5 mg
- Diabetes drug class confusion—SGLT2 inhibitor is not metformin, sulfonylurea, or DPP-4 inhibitor
- Perioperative hold missed—common high-risk error; flag on pre-op checklist and MAR
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Perioperative pathway | Hold ≥3 days before major surgery; communicate hold to pre-op team and patient; document restart criteria |
| EuDKA suspicion | Order ketones (blood or urine) when patient has acidosis symptoms—even if glucose is normal |
| Volume status | Track intake and output, daily weights, and orthostatic vitals especially with diuretics |
| Genital care | Teach hygiene after glucosuria; prompt reporting of genital pain or swelling |
| Commonly missed | Continuing home dose on NPO day; restarting too soon after surgery before oral intake stable |
| Ask pharmacy when | Indication unclear, eGFR near threshold, perioperative timing, or interaction with new diuretic/insulin orders |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Perioperative / NPO patients | Highest euDKA risk window—mandatory hold ≥3 days before major surgery per labeling |
| Older adults | Greater volume depletion and hypotension risk; closer I&O and orthostatic monitoring |
| Loop diuretic users | Additive diuresis—monitor renal function and blood pressure closely |
| Renal impairment | Indication-specific eGFR rules; do not use for glycemic control if eGFR <45 |
| Insulin-treated diabetes | Hypoglycemia risk plus euDKA risk—always assess ketones when clinically indicated |
| Pregnancy / lactation | Limited data; consult LactMed and prescriber—generally avoid unless benefit justifies risk |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood glucose, ketones when euDKA suspected, and BMP (anion gap, bicarbonate, creatinine)
- eGFR trends for indication eligibility—especially T2DM glycemic use vs CKD/HF continuation
- Blood pressure, orthostatic vitals, weight, and intake/output
- Genital skin and mucosa for infection; foot/perineal pain or erythema
- HbA1c periodically for glycemic indication
Document
- Indication, dose, hold status, and perioperative instructions on MAR
- Ketone assessment and prescriber notification when euDKA suspected
- Volume status interventions and patient teaching on hold/restart rules
Patient teaching
- Take once daily as prescribed; do not skip perioperative hold instructions from your care team
- Report persistent nausea, vomiting, abdominal pain, rapid breathing, or confusion immediately—even if blood sugar seems normal
- Maintain adequate fluids unless restricted; rise slowly from sitting to reduce dizziness
- Practice good genital hygiene; report pain, redness, swelling, or discharge promptly
- Do not restart after surgery or illness until your prescriber confirms you are eating normally and stable
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known serious hypersensitivity to dapagliflozin
- Scheduled major surgery within 3 days or current prolonged NPO/fasting—perioperative hold not yet implemented
- Suspected euDKA or metabolic acidosis with ketonuria/ketosis—regardless of blood glucose level
- Symptomatic hypotension, severe dehydration, or acute kidney injury likely related to volume depletion
- Signs of necrotizing fasciitis of the perineum (genital pain, erythema, swelling, fever)
- eGFR below indication threshold for glycemic use (<45) when prescribed solely for glucose lowering
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
SGLT2 inhibitors are increasingly ordered for HF and CKD—not only diabetes—so nurses on medical, surgical, and cardiology units must embed perioperative hold and euDKA assessment into routine passes, not only endocrine rounds.
1. Check-before-you-give protocol
- Right patient, dose, indication, and eGFR eligibility
- Perioperative hold verified on MAR and surgery schedule
- Volume status, orthostatic vitals, and concurrent diuretics reviewed
- Ketone assessment plan when nausea, tachypnea, or abdominal pain present
2. High-alert and safety badge
Perioperative hold & euDKA risk — assess ketones despite glucoseFDA labeling warns of euDKA with normal glucose and mandates SGLT2 hold before major surgery. Treat missed hold with the same urgency as insulin omission during DKA.
3. Clinical workflow: hold and question rules
- Pre-op day: if dapagliflozin appears on MAR within 3 days of surgery, hold and notify prescriber/pharmacy
- Post-op NPO: do not resume until eating, stable, and prescriber clears restart
- Any ketonuria with anion gap elevation triggers hold and euDKA pathway—even if glucose <200 mg/dL
4. Critical teach-back questions
- “When should you stop this medicine before surgery?” (Patient should reference care-team instructions and not taking it while fasting for surgery.)
- “What symptoms mean you need urgent care even if your sugar looks okay?” (Patient should name nausea/vomiting, belly pain, fast breathing, confusion.)
5. Care coordination
Pharmacist: Indication-specific renal thresholds, perioperative hold timing, insulin/SGLT2 interaction review
Prescriber / surgical team: Hold and restart orders, euDKA treatment, genital infection escalation
🧠 Quick mental checklist
- Is this patient NPO, post-op, or within 3 days of major surgery—and is dapagliflozin held?
- Does the indication match eGFR (T2DM glycemic vs CKD/HF 10 mg)?
- Any nausea, tachypnea, or abdominal pain—have ketones been checked despite glucose?
- Volume status: orthostatics, I&O, diuretics, and creatinine trend?
- Genital symptoms or perineal pain that could signal serious infection?
Dapagliflozin NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for dapagliflozin euDKA and perioperative safety using a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), metabolic trend interpretation, perioperative hold cloze, ordered response, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.
58-year-old with type 2 diabetes and heart failure is post-op day 1 after elective bowel surgery. Home dapagliflozin 10 mg daily and furosemide 40 mg daily. Currently NPO except ice chips; surgery was yesterday afternoon. The nurse is preparing the 0800 medication pass.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Dapagliflozin 10 mg PO daily — scheduled 0800; not yet given
- Furosemide 40 mg PO daily — given 0800
- Insulin lispro sliding scale — held while NPO per protocol
- Pre-op checklist: dapagliflozin hold ≥3 days — not documented
- Patient NPO; surgery completed yesterday 1400
- Admission: glucose 156 mg/dL; bicarbonate 24 mEq/L; anion gap 10
- Post-op day 1 (0600): glucose 168 mg/dL; bicarbonate 19 mEq/L; anion gap 16
- Urinalysis: ketonuria 2+; no UTI symptoms documented
- Creatinine 1.1 mg/dL (baseline 1.0); eGFR 72 mL/min/1.73 m²
- BP 98/62 mmHg (baseline 118/74); HR 108/min; RR 24/min
- Temp 37.4 °C; SpO₂ 96% on room air
- Orthostatics: BP 92/58 mmHg sitting → 86/52 mmHg standing; reports dizziness
- Intake 640 mL IV + 120 mL ice chips; output 420 mL (≈17 mL/h overnight)
- Patient reports nausea and generalized abdominal discomfort; denies chest pain
- Dry mucous membranes; poor oral intake since surgery
- Alert and oriented ×3 at 0700; mild fatigue
- Pre-op teaching: patient thought diabetes pills could continue until morning of surgery
- Pharmacy note pending: perioperative SGLT2 hold not entered in EMR
Answer key & rationale
Frequently asked questions
What is euglycemic DKA and why does dapagliflozin increase the risk?
Euglycemic diabetic ketoacidosis (euDKA) is ketoacidosis with blood glucose below the typical DKA threshold. SGLT2 inhibitors increase urinary glucose excretion and can shift metabolism toward ketogenesis during illness, reduced oral intake, surgery, or prolonged fasting. FDA labeling warns that euDKA has been reported—assess ketones when DKA is suspected regardless of blood glucose and discontinue dapagliflozin until resolved.
When must dapagliflozin be held before surgery or procedures?
Labeling recommends withholding dapagliflozin for at least 3 days before scheduled major surgery or any procedure associated with prolonged fasting. Resume only when the patient is clinically stable and has resumed oral intake. Verify hold status during preoperative medication reconciliation.
How does eGFR affect dapagliflozin dosing?
For type 2 diabetes glycemic control, dapagliflozin is not recommended when eGFR is below 45 mL/min/1.73 m². For CKD indication, 10 mg once daily may be used when eGFR is at least 25; initiation is not recommended if eGFR is below 25, but patients already on therapy for CKD may continue 10 mg if eGFR later falls below 25.
What volume-related adverse effects should nurses monitor?
Dapagliflozin causes osmotic diuresis leading to intravascular volume depletion, hypotension, dizziness, and acute kidney injury—especially with loop diuretics or poor intake. Monitor orthostatic vitals, intake and output, and creatinine. Hold and notify the prescriber when volume depletion is clinically significant.
Is there an antidote for dapagliflozin overdose?
No reports of overdose occurred in clinical development per labeling. Management is supportive care based on clinical status. Hemodialysis removal has not been studied, and no specific antidote is listed. Contact local poison control or toxicology services per facility protocol if overdose is suspected.
Can dapagliflozin cause genital infections?
Yes. Labeling reports genital mycotic infections and, rarely, necrotizing fasciitis of the perineum (Fournier gangrene). Teach patients to report genital pain, redness, swelling, malodorous discharge, or fever. Discontinue dapagliflozin if necrotizing fasciitis is suspected.
References
- U.S. National Library of Medicine. FARXIGA (dapagliflozin) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef9e9c8c-5460-4193-952a-0c249dd071bd
- U.S. National Library of Medicine. Dapagliflozin — Full prescribing information (generic). DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f56593f7-588e-489d-9fad-b459e90dab18
- U.S. Food and Drug Administration. FARXIGA (dapagliflozin) tablets — FDA approved labeling PDF. 2024.https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202356s035lbl.pdf
- Drugs and Lactation Database (LactMed). Dapagliflozin. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK500971/
- U.S. National Library of Medicine. Dapagliflozin — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a615043.html
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.https://www.accessdata.fda.gov/scripts/medwatch/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.